Popular Pre-Market Trades in US Stocks
X3, up 14.41% in pre-market, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.
Abivax SA is up 7.19% in pre-market. Based on recent key news:
<ol>
<li>
On January 12, French media La Lettre reported that US pharmaceutical giant Eli Lilly plans to acquire Abivax for €15 billion, driving the stock price up. Eli Lilly has not yet formally submitted a takeover bid and is awaiting approval from French regulators.
</li>
<li>
On January 12, Abivax's experimental drug obefazimod performed well in late-stage clinical trials for treating ulcerative colitis, making it a potential acquisition target. Kepler Cheuvreux analysts noted that the drug's success makes Abivax an attractive candidate for acquisition.
</li>
<li>
On January 12, analysts maintained a &#34;Buy&#34; rating on Abivax, with a target price of $145 to $153.88, reflecting market optimism regarding its potential acquisition. Mergers and acquisitions in the biotech industry are active, with significant capital inflow.
</li>
</ol>
Top Gainers in Pre-Market US Stocks
Agape ATP is up 60.71% in pre-market, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.
Mingteng is up 40.23% in pre-market. Based on recent key news:
<ol>
<li>
On January 14, Mingteng International completed capacity upgrades, aiming to increase mold production capacity by 50%. This news has driven market optimism regarding the company's future growth, leading to a significant rise in stock price. Source: Reuters
</li>
<li>
On January 12, Mingteng International announced an expansion of strategic cooperation with China's leading top suppliers of new energy vehicles to support sustainable development. This cooperation has enhanced market confidence in the company's development in the new energy sector, further driving up the stock price. Source: Reuters
</li>
<li>
On January 13, Mingteng's peers had an average short interest rate of 2.88%, lower than most peers. This indicates that market sentiment towards the company is relatively low, which may provide support for the stock price. Source: Benzinga. Cooperation in the new energy industry enhances market confidence.
</li>
</ol>
BRC is up 34.88% in pre-market. Based on recent news,
<ol>
<li>
On January 15, BRC Group Holdings released its third-quarter financial report, showing a significant improvement in net income, reaching $89.1 million, compared to a net loss of $286.4 million in the same period last year. Diluted earnings per share also turned from a loss of $9.39 per share in the third quarter of last year to earnings of $2.91 per share, with total revenue increasing to $277.9 million. Following the release of this financial report, the stock price rose 38.53% in after-hours trading
</li>
<li>
On January 13, the U.S. December CPI report showed moderate inflation, with the overall CPI increasing by 2.7% year-on-year and core inflation at 2.6%, slightly below market expectations. This trend may provide policy space for the Federal Reserve to cut interest rates in the first quarter, and the market reacted positively to this.
</li>
<li>
On January 15, Benzinga's stock ranking indicated that BRC Group Holdings was in the 91st percentile in terms of momentum, suggesting that its price trend has been positive across all time frames. The market has a positive outlook on the Federal Reserve's interest rate cut expectations
</li>
</ol>

XTKG

ABVX

X3 pre-market up 14.41%; Abivax SA pre-market up 7.19%; Agape ATP pre-market up 60.71%; Mingteng pre-market up 40.23%; BRC pre-market up 34.88%

Popular pre-market trades in US stocks: X3 pre-market up 14.41%; Abivax SA pre-market up 7.19%